Navigating the Success and Future Prospects of a Promising Smoking Cessation Asset| John Bencich, CEO, Achieve Life Sciences Inc. 00:10:00

Share On Facebook Share On Twitter

The interview discusses Achieve Life Sciences' lead asset, Cytisinicline, highlighting its successful progression from phase two to completion of two phase three trials, demonstrating strong efficacy and tolerability profiles. It also explores market demand for smoking cessation therapies amidst rising e-cigarette usage and the potentia.

Recent Videos